Form 4: Exelixis Director Stelios Papadopoulos Executes Stock Options and Sells Shares

Director Stelios Papadopoulos exercised stock options and sold shares of Exelixis, Inc. on May 15, 2025.

Summary

• On May 15, 2025, Stelios Papadopoulos, a director of Exelixis, Inc., executed options to purchase 20,634 shares at $19.77 and 15,874 shares at $20.5.
• Simultaneously, Papadopoulos sold 20,634 shares and 15,874 shares at $44.35 each.
• Following these transactions, Papadopoulos beneficially owns 1,279,416 shares of Exelixis common stock.
• This total includes 18,838 shares issuable upon the vesting of restricted stock units (RSUs).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, as mandated by the SEC.
• Similar filings can be observed for directors and officers at comparable biotech companies like Gilead Sciences (GILD) and Amgen (AMGN).

Stakeholder Impact

• The transactions may have a minor impact on shareholders, potentially influencing short-term stock price fluctuations.
• The filing provides transparency to stakeholders regarding insider trading activities.

Key Dates

Keywords

Exelixis, Stock Options, Form 4, Director, Share Sale, Beneficial Ownership, Papadopoulos, EXEL